Loading…
Lobbying Spend
—
Filings
232
Firms Hired
6
Active Period
2006–2024
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Elijah E. Cummings Lower Drug Costs Now Act
2022 · third_quarter · Firm: FEDERAL HEALTH POLICY STRATEGIES
Policies impacting the national stockpile H.R. 3--Elijah E. Cummings Lower Drug Costs Now Act Medicare sequestration Issues impacting drug pricing and reimbursement
Client expense: — · Firm income: $30,000
Matched citations: H.R. 3
Elijah E. Cummings Lower Drug Costs Now Act
2022 · third_quarter · Firm: FEDERAL HEALTH POLICY STRATEGIES
Policies impacting the national stockpile H.R. 3--Elijah E. Cummings Lower Drug Costs Now Act Medicare sequestration Issues impacting drug pricing and reimbursement
Client expense: — · Firm income: $30,000
Matched citations: H.R. 3
Elijah E. Cummings Lower Drug Costs Now Act
2022 · second_quarter · Firm: FEDERAL HEALTH POLICY STRATEGIES
Policies impacting the national stockpile H.R. 3--Elijah E. Cummings Lower Drug Costs Now Act Medicare sequestration Issues impacting drug pricing and reimbursement
Client expense: — · Firm income: $30,000
Matched citations: H.R. 3
Elijah E. Cummings Lower Drug Costs Now Act
2021 · fourth_quarter · Firm: FEDERAL HEALTH POLICY STRATEGIES
Policies impacting the national stockpile H.R. 3--Elijah E. Cummings Lower Drug Costs Now Act Medicare sequestration
Client expense: — · Firm income: $30,000
Matched citations: H.R. 3
Prescription Drug Pricing Reduction Act of 2019
2021 · third_quarter · Firm: LINCOLN POLICY GROUP
General healthcare issues S. 2543--Prescription Drug Pricing Reduction Act of 2019 COVID relief proposals
Client expense: — · Firm income: $10,000
Matched citations: S. 2543
Elijah E. Cummings Lower Drug Costs Now Act
2021 · third_quarter · Firm: FEDERAL HEALTH POLICY STRATEGIES
Policies impacting the national stockpile H.R. 3--Elijah E. Cummings Lower Drug Costs Now Act Medicare sequestration
Client expense: — · Firm income: $20,000
Matched citations: H.R. 3
Prescription Drug Pricing Reduction Act of 2019
2021 · second_quarter · Firm: LINCOLN POLICY GROUP
General healthcare issues S. 2543--Prescription Drug Pricing Reduction Act of 2019 COVID relief proposals
Client expense: — · Firm income: $40,000
Matched citations: S. 2543
Prescription Drug Pricing Reduction Act of 2019
2021 · first_quarter · Firm: LINCOLN POLICY GROUP
General healthcare issues S. 2543--Prescription Drug Pricing Reduction Act of 2019 COVID relief proposals
Client expense: — · Firm income: $40,000
Matched citations: S. 2543
Prescription Drug Pricing Reduction Act of 2019
2020 · fourth_quarter · Firm: LINCOLN POLICY GROUP
General healthcare issues S. 2543--Prescription Drug Pricing Reduction Act of 2019 COVID relief proposals
Client expense: — · Firm income: $40,000
Matched citations: S. 2543
Improving Transparency and Accuracy in Medicare Part D Spending Act
2020 · fourth_quarter · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
S. 988 and H.R. 803; legislation to prohibit prescription drug plan sponsors and MAPD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Issues related to pharmaceutical compounding and implementation of the Drug Quality Security Act (Pub.L. 113-54). FDA implementation of Section 503B of the FFDCA. Issues related to drug pricing and transparency, generally. Issues related to the importation of prescription medicines Issues related to the pharmaceutical supply chain and stockpiling Issues related to COVID vaccine distribution
Client expense: — · Firm income: $80,000
Matched citations: H.R. 803
Prescription Drug Pricing Reduction Act of 2019
2020 · fourth_quarter · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Medicare prompt pay discount exclusion, including legislation to ensure appropriate reimbursement for drugs and biologics under Medicare Part B by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's Average Sales Price (ASP). ASP, generally Medicare Part D, including removal of safe harbor protection for drug rebates Medicare Part B, including proposals to create an international pricing index and establish a competitive acquisition program Prescription Drug Pricing Reduction Act (S. 2543); inclusion of bona fide service fees in ASP calculation under Medicare Part B.
Client expense: — · Firm income: $80,000
Matched citations: S. 2543
Improving Transparency and Accuracy in Medicare Part D Spending Act
2020 · fourth_quarter · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
S. 988 and H.R. 803; legislation to prohibit prescription drug plan sponsors and MAPD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Issues related to pharmaceutical compounding and implementation of the Drug Quality Security Act (Pub.L. 113-54). FDA implementation of Section 503B of the FFDCA. Issues related to drug pricing and transparency, generally. Issues related to the importation of prescription medicines Issues related to the pharmaceutical supply chain and stockpiling Issues related to COVID vaccine distribution
Client expense: — · Firm income: $80,000
Matched citations: S. 988
Improving Transparency and Accuracy in Medicare Part D Spending Act
2020 · fourth_quarter · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Medicare prompt pay discount exclusion, including legislation to ensure appropriate reimbursement for drugs and biologics under Medicare Part B by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's Average Sales Price (ASP). ASP, generally Medicare Part D, including removal of safe harbor protection for drug rebates Medicare Part B, including proposals to create an international pricing index and establish a competitive acquisition program Prescription Drug Pricing Reduction Act (S. 2543); inclusion of bona fide service fees in ASP calculation under Medicare Part B. S. 988 and H.R. 803; legislation to prohibit prescription drug plan sponsors and MAPD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies.
Client expense: — · Firm income: $80,000
Matched citations: H.R. 803
Prescription Drug Pricing Reduction Act of 2019
2020 · fourth_quarter · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Medicare prompt pay discount exclusion, including legislation to ensure appropriate reimbursement for drugs and biologics under Medicare Part B by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's Average Sales Price (ASP). ASP, generally Medicare Part D, including removal of safe harbor protection for drug rebates Medicare Part B, including proposals to create an international pricing index and establish a competitive acquisition program Prescription Drug Pricing Reduction Act (S. 2543); inclusion of bona fide service fees in ASP calculation under Medicare Part B. S. 988 and H.R. 803; legislation to prohibit prescription drug plan sponsors and MAPD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies.
Client expense: — · Firm income: $80,000
Matched citations: S. 2543
Improving Transparency and Accuracy in Medicare Part D Spending Act
2020 · fourth_quarter · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Medicare prompt pay discount exclusion, including legislation to ensure appropriate reimbursement for drugs and biologics under Medicare Part B by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's Average Sales Price (ASP). ASP, generally Medicare Part D, including removal of safe harbor protection for drug rebates Medicare Part B, including proposals to create an international pricing index and establish a competitive acquisition program Prescription Drug Pricing Reduction Act (S. 2543); inclusion of bona fide service fees in ASP calculation under Medicare Part B. S. 988 and H.R. 803; legislation to prohibit prescription drug plan sponsors and MAPD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies.
Client expense: — · Firm income: $80,000
Matched citations: S. 988
Prescription Drug Pricing Reduction Act of 2019
2020 · third_quarter · Firm: LINCOLN POLICY GROUP
General healthcare issues S. 2543--Prescription Drug Pricing Reduction Act of 2019 COVID relief proposals
Client expense: — · Firm income: $40,000
Matched citations: S. 2543
Improving Transparency and Accuracy in Medicare Part D Spending Act
2020 · third_quarter · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to the Coronavirus Aid, Relief, and Economic Security (CARES) Acts SBA Paycheck Protection Program S. 988 and H.R. 803; legislation to prohibit prescription drug plan sponsors and MAPD organizations under Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Issues related to drug pricing and transparency, generally. Issues related to the importation of prescription medicines Issues related to the pharmaceutical supply chain
Client expense: — · Firm income: $80,000
Matched citations: H.R. 803
Prescription Drug Pricing Reduction Act of 2019
2020 · third_quarter · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to the Coronavirus Aid, Relief, and Economic Security (CARES) Acts Medicare Accelerated and Advance Payment Program Medicare prompt pay discount exclusion, including legislation to ensure appropriate reimbursement for drugs and biologics under Medicare Part B by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's Average Sales Price (ASP) Medicare Part D, including the removal of safe harbor protections for drug rebates Medicare Part B, including proposals to create an international pricing index and establish a competitive acquisition program Prescription Drug Pricing Reduction Act (S. 2543); inclusion of bona fide service fees in ASP calculation under Medicare Part B ASP, generally Issues related to the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs
Client expense: — · Firm income: $80,000
Matched citations: S. 2543
Improving Transparency and Accuracy in Medicare Part D Spending Act
2020 · third_quarter · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to the Coronavirus Aid, Relief, and Economic Security (CARES) Acts SBA Paycheck Protection Program S. 988 and H.R. 803; legislation to prohibit prescription drug plan sponsors and MAPD organizations under Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Issues related to drug pricing and transparency, generally. Issues related to the importation of prescription medicines Issues related to the pharmaceutical supply chain
Client expense: — · Firm income: $80,000
Matched citations: S. 988
Improving Transparency and Accuracy in Medicare Part D Spending Act
2020 · second_quarter · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to the Coronavirus Aid, Relief, and Economic Security (CARES) Acts SBA Paycheck Protection Program S. 988 and H.R. 803; legislation to prohibit prescription drug plan sponsors and MAPD organizations under Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Issues related to drug pricing and transparency, generally. Issues related to the importation of prescription medicines Issues related to the pharmaceutical supply chain
Client expense: — · Firm income: $80,000
Matched citations: H.R. 803
Prescription Drug Pricing Reduction Act of 2019
2020 · second_quarter · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to the Coronavirus Aid, Relief, and Economic Security (CARES) Acts Medicare Accelerated and Advance Payment Program Medicare prompt pay discount exclusion, including legislation to ensure appropriate reimbursement for drugs and biologics under Medicare Part B by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's Average Sales Price (ASP) Medicare Part D, including the removal of safe harbor protections for drug rebates Medicare Part B, including proposals to create an international pricing index and establish a competitive acquisition program Prescription Drug Pricing Reduction Act (S. 2543); inclusion of bona fide service fees in ASP calculation under Medicare Part B ASP, generally Issues related to the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs
Client expense: — · Firm income: $80,000
Matched citations: S. 2543
Improving Transparency and Accuracy in Medicare Part D Spending Act
2020 · second_quarter · Firm: ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC)
Issues related to the Coronavirus Aid, Relief, and Economic Security (CARES) Acts SBA Paycheck Protection Program S. 988 and H.R. 803; legislation to prohibit prescription drug plan sponsors and MAPD organizations under Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Issues related to drug pricing and transparency, generally. Issues related to the importation of prescription medicines Issues related to the pharmaceutical supply chain
Client expense: — · Firm income: $80,000
Matched citations: S. 988
Paycheck Protection Program and Health Care Enhancement Act
2020 · second_quarter · Firm: LINCOLN POLICY GROUP
General healthcare issues S. 2543--Prescription Drug Pricing Reduction Act of 2019 Paycheck Protection Program and Healthcare Enhancement Act (CARES Act 2.0) (H.R. 266)
Client expense: — · Firm income: $40,000
Matched citations: H.R. 266
Prescription Drug Pricing Reduction Act of 2019
2020 · second_quarter · Firm: LINCOLN POLICY GROUP
General healthcare issues S. 2543--Prescription Drug Pricing Reduction Act of 2019 Paycheck Protection Program and Healthcare Enhancement Act (CARES Act 2.0) (H.R. 266)
Client expense: — · Firm income: $40,000
Matched citations: S. 2543
General healthcare issues S. 2543--Prescription Drug Pricing Reduction Act of 2019 H.R. 748/S. 3548--CARES Act (Coronavirus Aid, Relief, and Economic Security Act) and covid-19 response
Client expense: — · Firm income: $40,000
Matched citations: H.R. 748
Source: Senate LDA